Lactobacillus rhamnosus for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Lactobacillus rhamnosus for Health & Longevity

Created on 09/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A live gut bacterium with a long clinical record. Firmest findings: shorter infectious diarrhea, protection against antibiotic-caused loose stools, fewer airway infections — mostly in children, weaker in adults. Results do not transfer between products. Safety is favorable when defenses are intact, serious when they are not. Nothing in the human record speaks to lifespan. (Full Review)

Protocol

Standard dose
1 × 10⁹ – 2 × 10¹⁰ colony-forming units daily
The 10-billion capsule is the most common commercial form.
Best time of day
Within thirty minutes before a meal containing some fat
Food buffers gastric acid; time of day itself has no established effect.
Single versus split dosing
Single morning dose
Matches most trial protocols; twice-daily restored vaginal flora.
Time to effect
Antibiotic-associated diarrhea
First days of the course
Trial windows spanned the course plus a week.
Mood and metabolic endpoints
Three to six months
Shorter trials are uninformative.
Inflammatory markers
Eight to twelve weeks
The shortest interval over which trials detected change.

Benefits

Contraindications
  • Immunosuppressive therapy (tacrolimus, ciclosporin, high-dose corticosteroids, biologics)
  • Neutrophil counts below 0.5 × 10⁹/L
  • Central venous catheters or vascular access
  • Prosthetic heart valves or prior infective endocarditis
  • Short bowel syndrome or documented mucosal breach
  • Active severe inflammatory bowel disease (Mayo endoscopic subscore 3)
  • Intensive care or mechanical ventilation
    •
Key Interactions
  • Antibiotics (amoxicillin, clarithromycin, ciprofloxacin): timing matters
  • Vancomycin and metronidazole: monitor
  • Antifungals (fluconazole, nystatin): no pharmacological interaction
  • Over-the-counter acid suppressants (omeprazole, famotidine): potentiating
  • Other supplement interactions (prebiotic fibers, other probiotic strains): additive
  • Other interventions (fecal microbiota transplantation, colonoscopy preparation): timing
    •

Risk & Side Effects

  • High: Bloodstream infection in compromised hosts
    •
  • Medium: Transient digestive symptoms; vaginal discharge and stool changes in pregnancy
    •
  • Low: D-lactic acidosis with cognitive fogging; deep-seated infection
    •
  • Speculative: Antibiotic resistance reservoir; delayed microbiome recovery after antibiotics
    •

Monitoring

Marker Target Why
High-sensitivity C-reactive protein Below 1.0 mg/L Low-grade inflammation; most likely to respond
Fecal calprotectin Below 50 µg/g Gut wall inflammation; flags mucosal breach
Complete blood count with differential Neutrophils above 1.5 × 10⁹/L Confirms defense against translocation
Glycated hemoglobin (HbA1c) 4.8–5.4% Three-month average blood sugar; conflicted signal
Erythrocyte sedimentation rate Below 15 mm/hr men, 20 women Slower-moving marker; useful when deep-seated infection is suspected
Fecal secretory immunoglobulin A No established target; individual's own baseline Gut immune activity; proposed immune mechanism

Cadence: Baseline panel before starting; inflammatory and metabolic markers at eight to twelve weeks, then every six to twelve months. Unexplained fever prompts blood cultures.

Qualitative Assessment

  • Bowel habit — stool form and frequency, against a Bristol Stool Form Scale reference
  • Bloating and gas in the two hours after meals
  • Frequency and duration of upper-respiratory episodes over a winter
  • Perceived stress and mood stability under a known recurring stressor
  • Digestive tolerance of an antibiotic course versus previous courses
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.